Huons Meditech, a leading medical device company within the Huons Group, has launched its premium needles in China, marking a significant step in its market expansion strategy.
The company announced on Wednesday that it has successfully registered its specialized skin booster needle, the Premium 9-Pin Needle, with China’s National Medical Products Administration (NMPA).
This innovative needle is designed to complement Huons Meditech’s flagship aesthetic injection devices, the Dermashine Pro and Dermashine Balance.
The Premium 9-Pin Needle boasts a sophisticated design that enhances its compatibility with these devices, ensuring a stable treatment environment even during high-pressure drug injections.
A key feature is its optimized inner diameter, which allows for precise delivery of viscous substances deep into the skin without leakage, dramatically reducing product waste.
The needle’s design also prioritizes user experience. Its specialized bevel gear configuration minimizes patient discomfort and recovery time, while a dedicated protective cap safeguards practitioners against accidental needlestick injuries.
This NMPA certification paves the way for Huons Meditech to expand its footprint in the global aesthetic market, with a particular focus on China, as the company continues to develop and introduce cutting-edge medical devices.
Ha Chang-woo, Chief Executive Officer (CEO) of Huons Meditech, expressed confidence in the company’s latest achievement: By integrating the innovative Premium 9-Pin Needle with the globally recognized Dermashine platform, they’ve created a comprehensive solution for aesthetic treatments. This NMPA approval strengthens the position as a trusted partner for aesthetic professionals in China’s growing skin booster market.
